Down 8.4% today, more than its medical device peers' 0.3%; no story names it yet.
Lags the market
Down 17% in a year while the S&P 500 rose 12%; up 108% over three years.
STIM's Quality Score fell 5 points on Mon, Nov 2, to -5. Its price fell below its average of the last 21 days (3 chart checks stopped). 1 more reason, for Pro members.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
| Since its 2022 high | Down 67% |
| Latest filing | 10-Q, Aug 11 |
TodayNo story names it yet.
After its last 4 reports it closed +12.0% on average, higher 3 of 4 times.
Poorfor quality, not price, 0 of 14 chart checks firingWhat the Quality Score means
Well below its recent run. STIM scores -5 today, against a median of 1 over its last 20 recorded sessions.
STIM is #79 of 85 by Quality Score.
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 79 |
Reports Wed Nov 4, before the open (in 2 days). Confirmed.
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
The figures are not read from the release yet.
“The increase was primarily driven by higher Greenbrook revenue, which increased to $26.9 million in the second quarter of 2026 from $23.0 million in the second quarter of 2025, reflecting continued growth of the Greenbrook business.”
STIM's results filing gives no sales by line in a table we read.
| Measure | Figure |
|---|---|
| Total revenue | $160M to $164M |
Sales grew 32% a year over 3 years, fiscal 2022 to 2025.
| Reported | Gap | Reaction | 5 sessions |
|---|---|---|---|
| Aug 11, 2026 | +26.0% | +47.0% | +50.7% |
| May 5, 2026 | +2.5% | +7.4% | -25.5% |
| Mar 17, 2026 | -10.7% | -9.9% | +17.6% |
Sales grew in six of the last seven years, to $149M in 2025. It lost money in each of the eight years.
One insider bought $901K across 5 filings in the last 6 months. No open-market sales on record. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: STIM is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
Neuronetics Inc a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advance Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advance Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address the existing treatment options. The company operates in two segments: medical devices and clinic services.
“We have competitors that sell other forms of TMS therapy, including Brainsway, Apollo TMS, Magstim, MagVenture, CloudTMS and Nexstim, that compete directly with the NeuroStar Advanced Therapy System.”
STIM scores -5 today, which Breakaway calls Poor. It is #79 of 85 in Medical Devices by Quality Score, with 0 of 14 chart checks firing. Down 17% in a year while the S&P 500 rose 12%; up 108% over three years. Shares: 10.5% more than a year ago (to Jun 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
STIM scores -5 today, which Breakaway calls Poor (below zero). That is #79 of 85 in Medical Devices by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind STIM's -5.
One insider bought $901K across 5 filings in the last 6 months. No open-market sales on record. The newest is Jorey Chernett, 10% owner, who bought $41K on Oct 30. Every filing, with the scored weight, for Pro members.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.